Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.18 is 242% below its 5-year average of -0.64, near the low end of its 5-year range (-2.18–0.08).
163.05% below its 12-month average of -0.83.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.63.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 17 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:08:17.904Z. Historical observations retain their original dates. Historical series through 2025-05-14.
EARNINGS PER SHARE (EPS)
-2.18
EARNINGS PER SHARE (EPS) AVG TTM
-0.83
EARNINGS PER SHARE (EPS) AVG 3Y
-0.77
EARNINGS PER SHARE (EPS) AVG 5Y
-0.64
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-163.05%
CURRENT VS 3Y AVG
-181.52%
CURRENT VS 5Y AVG
-241.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ARS Pharmaceuticals, Inc.
Market Cap
$426.13M
Earnings Per Share (EPS)
-2.18
TTM Avg
-0.83
3Y Avg
-0.77
5Y Avg
-0.64
Market Cap
$426.64M
Earnings Per Share (EPS)
-1.33
TTM Avg
-17.45
3Y Avg
-17.77
5Y Avg
-15.77
Market Cap
$425.21M
Earnings Per Share (EPS)
-1.98
TTM Avg
-3.65
3Y Avg
-4.15
5Y Avg
-2.79
Market Cap
$424.75M
Earnings Per Share (EPS)
-0.84
TTM Avg
-3.40
3Y Avg
-3.01
5Y Avg
-2.22
Market Cap
$430.46M
Earnings Per Share (EPS)
-0.75
TTM Avg
-2.34
3Y Avg
-2.48
5Y Avg
-2.46
Market Cap
$419.61M
Earnings Per Share (EPS)
-2.27
TTM Avg
-2.08
3Y Avg
-0.07
5Y Avg
-5.01
Market Cap
$437.20M
Earnings Per Share (EPS)
-4.57
TTM Avg
-3.99
3Y Avg
-6.52
5Y Avg
-18.52
Market Cap
$414.70M
Earnings Per Share (EPS)
-4.63
TTM Avg
-6.16
3Y Avg
-6.16
5Y Avg
-6.16
Market Cap
$412.48M
Earnings Per Share (EPS)
-5.18
TTM Avg
-2.77
3Y Avg
-1.90
5Y Avg
-1.90
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | $426.13M | -2.18 | -0.83 | -0.77 | -0.64 |
| Tilray Brands, Inc. (TLRY)vs › | $426.64M | -1.33 | -17.45 | -17.77 | -15.77 |
| NeoGenomics, Inc. (NEO)vs › | $425.21M | -1.98 | -3.65 | -4.15 | -2.79 |
| Prothena Corporation plc (PRTA)vs › | $424.75M | -0.84 | -3.40 | -3.01 | -2.22 |
| Editas Medicine, Inc. (EDIT)vs › | $430.46M | -0.75 | -2.34 | -2.48 | -2.46 |
| Senseonics Holdings, Inc. (SENS)vs › | $419.61M | -2.27 | -2.08 | -0.07 | -5.01 |
| Tectonic Therapeutic, Inc. (TECX)vs › | $437.20M | -4.57 | -3.99 | -6.52 | -18.52 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $414.70M | -4.63 | -6.16 | -6.16 | -6.16 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $412.48M | -5.18 | -2.77 | -1.90 | -1.90 |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.94M | 0.55 | -3.62 | -10.86 | -15.74 |
Trailing EPS (TTM)
$-2.18
Forward EPS (Est.)
$-1.78
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.74 |
| 2024-12-31 | 0.08 |
| 2023-12-31 | -0.57 |
| 2022-12-31 | -0.87 |
| 2021-12-31 | -0.70 |
| 2020-12-31 | -0.03 |
| 2019-12-31 | -0.72 |
| 2018-12-31 | -0.53 |
